#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10716	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2192	483.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1423	1423	C	634	C	618	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10716	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2192	483.5	0	HET	.	.	.	A1138G,C	.	1138	1138	A	1377	1377	A	575	A,G,C	402,136,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19606	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3723	524.0	0	.	n	.	0	T695C	SNP	695	695	T	1108	1108	C	618	C,A	599,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19606	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3723	524.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1750	1750	A	650	A,G	642,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19606	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3723	524.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2384	2384	C	578	C,G	565,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19606	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3723	524.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3010	3010	T	524	T,C	508,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19606	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3723	524.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2458	2458	A	631	A	613	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1320	folP	852	852	100.0	folP.l15.c4.ctg.1	1568	83.5	1	SNP	p	R228S	1	.	.	682	684	AGC	1082	1084	AGC	135;137;140	A;G;C	131;133;136	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3678	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	107.6	1	SNP	p	S91F	0	.	.	271	273	TCC	586	588	TCC	123;123;122	T;C;C,T	119;118;115,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3678	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	107.6	1	SNP	p	D95G	0	.	.	283	285	GAC	598	600	GAC	111;113;110	G;A;C	106;108;108	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3678	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	107.6	1	SNP	p	D95N	0	.	.	283	285	GAC	598	600	GAC	111;113;110	G;A;C	106;108;108	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	0	.	p	.	0	C66trunc	TRUNC	196	196	T	604	604	T	127	T	123	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	0	.	p	.	0	D79N	NONSYN	235	237	GAT	643	645	AAT	118;118;119	A;A;T	117;118;116	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	0	.	p	.	0	G83E	NONSYN	247	249	GGT	655	657	GAA	126;127;128	G;A;A	123;124;126	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	721	723	CAC	148;149;149	C,T;A;C	145,1;142;146	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	0	.	p	.	0	A134T	NONSYN	400	402	GCA	808	810	ACA	116;115;115	A;C;A	112;111;112	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	531	1090	mtrR	633	633	97.95	mtrR.l15.c17.ctg.1	1393	77.7	1	SNP	p	G45D	0	.	.	133	135	GGC	541	543	GGC	161;162;161	G;G,A;C	156;155,1;158	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3638	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2908	124.3	1	SNP	p	D86N	0	.	.	256	258	GAC	575	577	GAC	139;139;143	G;A;C	136;131;137	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3638	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2908	124.3	1	SNP	p	S87I	0	.	.	259	261	AGT	578	580	AGT	145;146;146	A,C;G;T,C	138,1;140;133,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3638	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2908	124.3	1	SNP	p	S87W	0	.	.	259	261	AGT	578	580	AGT	145;146;146	A,C;G;T,C	138,1;140;133,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3638	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2908	124.3	1	SNP	p	S87R	0	.	.	259	261	AGT	578	580	AGT	145;146;146	A,C;G;T,C	138,1;140;133,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	3638	parC	2304	2304	100.0	parC.l6.c4.ctg.1	2908	124.3	1	SNP	p	S88P	0	.	.	262	264	TCC	581	583	TCC	145;146;145	T;C;C	138;140;141	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2872	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2640	107.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1558	1560	GGC	134;131;131	G;G;C	132;129;128	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1286	1288	GCA	142;144;145	G;C;A	137;140;141	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1289	1291	ATC	146;147;146	A;T;C	142;145;142	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1301	1303	GTG	151;150;149	G;T;G	148;144;147	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1301	1303	GTG	151;150;149	G;T;G	148;144;147	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1805	1807	ACC	131;132;132	A;C;C	123;126;126	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1859	1861	GCG	120;118;120	G;C,G;G	107;98,2;113	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1859	1861	GCG	120;118;120	G;C,G;G	107;98,2;113	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1982	1984	GGC	110;108;105	G;G;C	103;102;99	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1991	1993	GGC	102;102;101	G;G;C	94;96;94	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	2700	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2338	114.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2009	2011	CCG	78;78;80	C;C,G;G	73;70,1;68	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3966	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3183	124.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1736	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1859	92.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	550	550	C	105	C	96	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	S271T	NONSYN	811	813	TCG	47	49	ACT	47;47;46	A;C;T	39;39;38	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	53	55	GAT	41;41;39	G;A;T	39;39;39	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	D276N	NONSYN	826	828	GAT	62	64	AAC	39;39;39	A;A;C	38;39;39	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	N277H	NONSYN	829	831	AAC	65	67	CAC	39;39;39	C;A;C	39;39;38	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	R307E	NONSYN	919	921	AGA	155	157	GAA	16;16;16	G;A;A	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	T311A	NONSYN	931	933	ACA	167	169	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	E312D	NONSYN	934	936	GAA	170	172	GAC	16;16;16	G;A;C	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	F314I	NONSYN	940	942	TTC	176	178	ATC	16;16;15	A;T;C	16;16;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	A316S	NONSYN	946	948	GCG	182	184	TCG	14;14;13	T;C;G	13;14;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	V318A	NONSYN	952	954	GTC	188	190	GCC	14;14;14	G;C;C	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	G319S	NONSYN	955	957	GGC	191	193	AGC	13;14;13	A;G;C	12;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	G320A	NONSYN	958	960	GGT	194	196	GCC	14;15;14	G;C;C	12;15;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	246	porB1a	984	220	90.45	porB1a.l15.c30.ctg.2	296	24.6	0	.	p	.	0	G322V	NONSYN	964	966	GGT	200	202	GTT	14;14;14	G;T;T	13;14;14	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	384	386	GGA	171;171;170	G;G,A;A	164;163,1;163	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	F135L	NONSYN	403	405	TTT	645	647	CTT	148;149;148	C;T;T	147;147;146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	R143G	NONSYN	427	429	AGA	669	671	GGA	142;140;140	G,T;G;A	138,1;138;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	D171G	NONSYN	511	513	GAT	753	755	GGT	140;141;141	G,A;G,A;T,C	134,1;137,1;130,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	G189S	NONSYN	565	567	GGC	807	809	AGC	150;152;152	A;G;C	145;150;149	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	873	873	T	148	T,A	139,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	1	SNP	p	G120K	0	.	.	358	360	GGT	600	602	GGT	134;131;132	G;G;T	130;128;122	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	1	SNP	p	A121D	0	.	.	361	363	GCC	603	605	GCC	132;132;133	G;C,A;C	131;130,1;131	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2054	porB1b	1035	1035	96.0	porB1b.l15.c17.ctg.1	1408	142.8	1	SNP	p	A121N	0	.	.	361	363	GCC	603	605	GCC	132;132;133	G;C,A;C	131;130,1;131	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	7336	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4857	150.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1919	1921	AAT	159;159;160	A,C;A;T	152,1;153;152	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	798	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1022	77.5	1	SNP	p	V57M	1	.	.	169	171	ATG	518	520	ATG	141;140;144	A;T;G	137;135;141	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
